About Anokion
Anokion is a company based in Ecublens (Switzerland) founded in 2010. Anokion has raised $112.5 million across 3 funding rounds from investors including Pfizer, Celgene and Novo Holdings. The company has 30 employees as of December 31, 2023. Anokion has completed 1 acquisition, including Kanyos Bio. Anokion offers products and services including SynCeD, ACeD-it, ACeD, and MoveS-it. Anokion operates in a competitive market with competitors including Moderna, BeiGene, Biogen, Incyte and Vir Biotechnology, among others.
- Headquarter Ecublens, Switzerland
- Employees 30 as on 31 Dec, 2023
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Anokion Us Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$112.5 M (USD)
in 3 rounds
-
Latest Funding Round
$35 M (USD), Series B
Oct 18, 2022
-
Investors
Pfizer
& 4 more
-
Employee Count
30
as on Dec 31, 2023
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Anokion
Anokion offers a comprehensive portfolio of products and services, including SynCeD, ACeD-it, ACeD, and MoveS-it.
Platform for celiac disease treatment via immune tolerance.
Targets celiac disease with antigen-specific interventions.
Focuses on celiac disease immune tolerance therapies.
Develops treatments for multiple sclerosis using tolerance methods.
People of Anokion
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Anokion
Anokion has successfully raised a total of $112.5M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $35 million completed in October 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Anokion
Anokion has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, Celgene and Novo Holdings.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked | |
|
Investments are made in innovative life science companies globally.
|
Locked | Locked | Locked | |
|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
|
Locked | Locked | Locked |
Investor details for Anokion
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Anokion
Anokion has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Kanyos Bio.
Investment portfolio details for Anokion
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Antigen-specific immune tolerance technology for two specific autoimmune indications, type-1 diabetes and celiac disease
|
Locked | Locked | 2015 | Locked |
Complete acquisition details for Anokion
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Anokion
Detailed financials for Anokion
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Anokion Comparisons
Peer comparison for Anokion
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Anokion
Anokion operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Biogen, Incyte and Vir Biotechnology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of infectious diseases
|
|
| Locked | Locked | Locked |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
Detailed competitors of Anokion
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Anokion
Complete news archive for Anokion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Anokion
Anokion was founded in 2010 and raised its 1st funding round 4 years after it was founded.
Anokion is headquartered in Ecublens, Switzerland. It is registered at Ecublens, Vaud, Switzerland.
Anokion is a funded company, having raised a total of $112.5M across 3 funding rounds to date.
As of Dec 31, 2023, the latest employee count at Anokion is 30.
Anokion was founded in 2010 in Ecublens, Switzerland, within the biotechnology sector. Therapeutic proteins are developed using antigen-specific immune tolerance technology to address autoimmune and allergic diseases. The platform is designed to reduce immunogenicity of proteins and enable treatments across various clinical indications. Operations focus on translating this technology to multiple protein-based therapies for immune-related conditions.
Anokion's top competitors include Moderna, BeiGene and ADMA Biologics.
Anokion offers SynCeD, ACeD-it, ACeD, and MoveS-it.
Anokion has made 1 acquisition, including Kanyos Bio.
Anokion has 5 investors. Key investors include Pfizer, Celgene, Novo Holdings, Novartis Venture Fund, and Versant Ventures.